Red blood cell ATP/ADP & nitric oxide: The best vasodilators in diabetic patients
© Bakhtiari et al.; licensee BioMed Central Ltd. 2012
Received: 6 August 2012
Accepted: 6 August 2012
Published: 24 August 2012
Diabetes mellitus is a group of metabolic diseases characterized by high blood sugar (glucose) levels that result from defects in insulin secretion, or action, or both. Inspired by previous report the release of ATP from RBCs, which may participate in vessel dilation by stimulating NO production in the endothelium through purinergic receptor signaling and so, the aim of this study is to clearly determined relationship between RBC ATP/ADP ratio with nitric oxide.
The ATP/ADP ratio of erythrocytes among four groups of normal individuals (young & middle age), athletes’ subjects and diabetic patients were compared and the relationship between ATP/ADP ratio and NO level of plasma was determined with AVOVA test and bioluminescence method.
ATP/ADP level in four groups normal (young & middle age), athletes, diabetes] are measured and analyzed with ANOVA test that show a significant difference between groups (P-value < 0.001). A significant positive correlation was found between RBC ATP/ADP content (r = 0.705; P < 0.001). Plasma NO content is also analyzed with ANOVA test which shows a significant difference between groups.
In this study, a positive relationship between RBC ATP/ADP ratio and NO was found. Based on the obtained result, higher RBC ATP/ADP content may control the ratio of plasma NO in different individuals, also this results show that ATP can activate endothelial cells in NO production and is a main factor in releasing of NO from endothelial cells.
KeywordsDiabetes ATP/ADP Nitric oxide Red blood cell
Diabetes mellitus is a group of metabolic diseases which interfere with energy homeostasis . Diabetes is one of the most costly chronic diseases with an estimated worldwide prevalence of 170 million in 2002, which is expected to double by 2030 according to the World Health Organization . The most common macrovascular complication of diabetes is atherosclerosis, which increases the risk for myocardial infarction, stroke, and peripheral artery disease, the latter being the leading cause of limb amputation in civilized countries. Microvascular complications consist of retinopathy and nephropathy, the leading causes of blindness and renal failure . There is now substantial evidence indicating that endothelial dysfunction, characterized by diminished endothelium dependent relaxation, is abnormal in experimental models of diabetes [4–8]. Several other studies have also demonstrated impaired endothelium dependent vasodilation in human diabetic patients [9, 10]. There is substantial evidence suggesting that high concentrations of glucose could reduce NO availability due to an increase in superoxide anion production . Further, elevated glucose levels may lead to a decrease in cellular concentrations of nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH) through activation of the polyol pathway . As NADPH is an essential cofactor of NO synthase (NOS) for NO synthesis, its depletion could lead to a reduction in endothelial NO production. NO mediates the endothelium-dependent vasodilation in response to stimuli such as shear stress, insulin, and acetylcholine . Recent evidence suggests that NO interacts with other flow-induced vasodilation mediators, including prostacyclin and adenosine, and this interaction results in net hemodynamic changes. NO has also been shown to mediate exercise-induced vasodilation . As a potent endogenous vasodilator, NO has numerous beneficial effects that preserve normal vascular function. For example, NO activates guanylate cyclase in vascular smooth muscle, and increases the production of cyclic guanosine monophosphate (cGMP). cGMP, as a second messenger, mediates many of the biological effects of NO, e.g. causing relaxation of smooth muscle and inhibiting platelet aggregation . In addition, NO inhibits platelet activation and adhesion to the surface of endothelium. NO reduces vascular oxidative stress and inhibits superoxide generation [16, 17]. In addition, NO stimulates angiogenesis, which plays an important role in wound healing, vascular remodeling, and conditions like myocardial infarction and diabetic retinopathy . NO is also a mediator of the immune response, a neurotransmitter, a cytotoxic free radical and a widespread signaling molecule [16, 18]. NO stimulates insulin release from pancreatic ß cells in the presence of glucose . These properties suggest that the level of NO production by the endothelium may play a pivotal role in the regulation of vascular disease. Therefore, impaired endothelial NO production may constitute a critical manifestation of proatherogenic events in the vascular wall, including increased vascular tone, platelet aggregation, endothelial barrier dysfunction, vascular inflammation, and smooth muscle cell proliferation. Nisoli et al  recently reported that the NO-cGMP-dependent pathway controls mitochondrial biogenesis and body energy balance. For example, NOS null mutant mice had a reduced metabolic rate and accelerated weight gain , insulin resistance , hypertension, and hyperlipidemia . Accordingly, it was reported that the red blood cell (RBC) is a determinant of endogenous nitric oxide (NO) synthesis in the pulmonary circulation; i.e., in the isolated perfused rabbit lung, RBCs obtained from either rabbits or healthy humans were required component of the perfusate in order to demonstrate flow-induced endogenous NO synthesis . RBCs contain concentrations of ATP adequate to activate the endothelial P2y purinergic receptors, resulting, thereby, in synthesis of NO [24, 25]. Importantly, the component of blood, responsible for the stimulation of endogenous NO synthesis, was determined to be the RBC, via the release of adenosine triphosphate (ATP) . Indeed, the application of ATP to endothelial cells resulted in an increase in NO synthesis [24, 27]. ATP is of particular interest because it is present in millimolar amounts in RBCs . In the present study, we investigated the RBC ATP/ADP ratio and plasma nitric oxide in different groups (normals, diabetes). We characterized a significant coherency between ATP/ADP and nitric oxide .in addition, in this study we determined these factors in athletics’ subject, all of them were jodo national team. Finally, to bold the results, they comparison with each other.
Materials and methods
In this study we investigated on human subjects, all control subjects were healthy volunteer living in the community, and none was acutely ill. None exhibited evidence of cardiac or chronic kidney disease and all were euthyroid with normal liver function tests and normal value for plasma urea, creatinine and electrolytes. Furthermore, healthy subjects were drug free and with a negative family history of diabetes mellitus or hypertension. The subjects were fully informed of any risks and discomforts associated with the experiments before giving their informed written consent to participate. The studies conformed to the code of Ethics of the World Medical Association (Declaration of Helsinki) and were approved by the Ethics Committee of Shariati Hospital, Tehran University of Medical Science of Iran. RBC of 40 uncontrolled diabetes patients was collected (40-65 years) and at the time of the study (HbA1C% 8.79 ± 0.19) we also collected RBC from 60 healthy volunteer (23-55 years), this group was divided into three classes, normals [young individuals ( 20-33 years) and middle age subjects ( 40-55 years)] and athletes (20-33 years). The following parameters were determined in all blood samples which collected at early morning after overnight fast: erythrocyte ATP, ADP content and plasma nitric oxide (NO) level.
ATP assay method in RBC
ATP was measured by luciferin-luciferase technique [29, 30]. In which the amount of light generated by the reaction of ATP with recombinant luciferase is dependent on the ATP concentration. Sensitivity was augmented by addition of the D-luciferin to the luciferase. A, 50 μl sample of RBC, lysed with TCA 10% (tricoloroaceticacid) and neutralized with KOH 1 M and diluted with hepes buffer 100 mM pH 7.8 (1:64), injected into a cuvette containing 10 μl luciferin (sigma), 10 μl Mgso4, 10 μl luciferase(1 mg/ml). The peak light efflux from cuvette to which either known ATP standards or samples are added was determined using a luminometer (Sirius tube Luminometer, Berthold Detection System, Germany), a ATP standard curve was obtained on the day of each experiment.
RBC ADP assay procedure
ADP was measured by the coupled assay of pyruvate kinase with luciferin-luciferase technique , in which at first we injected 5 μl pyruvate kinase (1 mg/ml) into a cuvettes containing 50 μl RBC (lysed, neutralized and diluted), 5 μl PEP (phospho enol pyruvate 20 mM, sigma), 5 μl KCl and patience for 7 min since the ADPs existed in the sample converted to ATP, then added 10 μl luciferin (10 mM), 10 μl luciferase (1 mg/ml) and 10 μl Mgso4. The peak light efflux from cuvette to which either known ADP standards or samples are added was determined using a luminometer, an ADP standard curve was obtained on the day of each experiment.
NO assay procedure
NO was measured by the dye assay based on Griess reaction . In this study to inhibition of blurred solution which interferes with assay we used Znso4 as a protein degenerative (solution clarification) [33, 34]. In this assay which act based on Griess reaction, added 100 μl a mixture of solution, NEDD (N-1-naphtylethylenediamine) and sulphanomide (1:1) to 100 μl of clarified serum, to doing reaction and dye forming, solution mixture placed into incubator 37°C for 30 min. after this time dye formed from this reaction measured at 540 nm by Elisa reader ( Sunrisa, Tecan, Austrian).
Statistical significance among experimental periods and groups was determined with analysis of variance, Tamhane test and Scheffe test for multiple comparisons, Bivariate correlation for relation between variables and regression for prediction. A P-value 0.05 or less was considered statistically significant. Results are reported as the means ± SEM.
Human subject studied
Age and sex characteristics of studied subjects: Erythrocyte ATP/ADP and plasma NO content, Tamhan test for ATP/ADP group comparison, as shown in this table the difference between groups are significant (P-value <0.001)
26.7 ± 0.49
50 ± 0.60
27.7 ± 0.61
60 ± 1.7
3.08 ± 0.09
2.4 ± 0.07
4.96 ± 0.411
1.26 ± 0.08
38.27 ± 1.4
31 ± 1.65
50.58 ± 1.33
25.37 ± 0.96
4.86 ± 0.13
5.31 ± 0.11
4.09 ± 0.08
8.79 ± 0.19
84.05 ± 2.5
102.5 ± 2.7
76 ± 0.94
172 ± 5.9
ATP/ADP level between groups
NO level between groups
Correlation between RBC ATP/ADP content and NO
A significant positive correlation was found between RBC ATP/ADP content (r = 0.705; P < 0.001). In this study, a positive relationship between ATP/ADP and NO is found, accordingly; 0.705 unit increase in NO is accompanied by 1 unit increase of ATP/ADP ratio. Therefore, based on experimental measurements reported here, using B Coefficient a formula for prediction of ATP/ADP ratio could be obtained : ATP/ADP = -0.990 + 0.105 [NO].
Pearson correlation between ATP/ADP and NO, this table showed that if NO 0.705 increased ATP/ADP level 1 unit increased
In conclusion, according to the result obtained in this investigation; the relationship between RBC ATP/ADP ratio and plasma NO is a positive significant and have a reciprocal correlation these factors was high in athletes and normal individuals in comparison with diabetic patients. It seems that ATP/ADP content may be considered as a main stimulator for NO secretion from endothelial cells, diabetes control and diabetic consequence such as stroke.
I'll be appreciate from all of collaborate in this project specially authors’ manuscript which do their best in progress this idea.
- Huiyun L, Walter F: Ward PGC-1alpha, a key regulator of energy metabolism. Adv Physiol Educ 2006, 30:145–151.View Article
- Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053.PubMedView Article
- Sobel BE, Schneider DJ: Cardiovascular complications in diabetes mellitus. Curr Opin Pharmacol 2005, 5:143–148.PubMedView Article
- Pieper GM, Moore-Hilton G, et al.: Evaluation of the mechanism of endothelial dysfunction in the genetically-diabetic BB rat. Life Sci 1996, 58:147–152.
- Rosen P, Ballhausen T, Bloch W, et al.: Endothelial relaxation is disturbed by oxidative stress in the diabetic rat: influence of tocopherol as antioxidant. Diabetologia 1995, 38:1157–1168.PubMedView Article
- Pieper GM, Peltier BA: Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995, 25:397–403.PubMedView Article
- Pieper GM, Jordan M, Adams MB, et al.: Syngeneic pancreatic islet transplantation reverses endothelial dysfunction in experimental diabetes. Diabetes 1995, 33:1106–1113.View Article
- Meininger CJ, Marinos RS, Hatakeyama , et al.: Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J 2000, 349:353–356.PubMedView Article
- Calver A, Collier J, Vallance PJ: Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulindependent diabetes. Clin. Invest 1992, 90:2548–2554.View Article
- Elliott TG, Cockcroft JR, Groop PH, et al.: Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci (Lond) 1993, 85:687–693.
- De Vriese AS, Verbeuren TJ, Vande VJ: Endothelial dysfunction in diabetes mellitus. Br J Pharmacol 2000, 130:963–974.PubMedView Article
- Chan N, Vallance P, Colhoun HM: Nitric oxide and vascular responses in type-I diabetes. Diabetologia 2000, 43:137–147.PubMedView Article
- Shankar RR, Wu Y, Shen H, Zhu JS, et al.: Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin. Diabetes 2000, 49:1–4.View Article
- Boger RH, Bode-Boger SM, Frolich JC: The L-arginine-nitric oxide pathway. role in atherosclerosis and therapeutic implications. Atherosclerosis 1996, 127:1–11.PubMedView Article
- Wu G, Meininger CJ: Arginine nutrition and cardiovascular function. J Nutr 2000, 130:2626–2629.PubMed
- Flynn NE, Meininger CJ, Haynes TE, et al.: The metabolic basis of arginine nutrition and pharmacotherapy. Biomed Pharmacother 2002, 56:427–438.PubMedView Article
- Napoli C, Ignarro LJ: Nitric oxide and atherosclerosis. Nitric Oxide: Biology and Chemistry 2001, 5:88–97.View Article
- Wu G, Meininger CJ: Regulation of nitric oxide synthesis by dietary factors. Annu Rev Nutr 2002, 22:61–86.PubMedView Article
- Mendez JD, Balderas F: Regulation of hyperglycemia and dyslipidemia by exogenous L-arginine in diabetic rats. Biochimie 2001, 83:453–458.PubMedView Article
- Nisoli E, Clementi E, Paolucci C, et al.: Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003, 299:896–899.PubMedView Article
- Shankar RR, Wu Y, Shen H, et al.: Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin. Diabetes 2000, 49:1–4.View Article
- Duplain H, Burcelin R, Cook S, et al.: Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001, 104:342–351.PubMedView Article
- Sprague RS, Stephenson AH, Dimmitt RA, et al.: Effect of L-NAME on pressure-flow relationships in isolated rabbit lungs. Am J Physiol 1995, 269:H1941-H1948.PubMed
- Bogle RG, Coade SB, Moncada S, et al.: Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem Biophys Res Commun 1991, 80:926–932.View Article
- Busse R, Ogilvie A, Pohl U: Vasomotor activity of diadenosine triphosphate and diadenosine tetraphosphate in isolated arteries. Am J Physiol 1988, 254:H828-H832.PubMed
- Sprague RS, Ellsworth ML, Stephenson AH, et al.: ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am J Physiol 1996, 271:H2717-H2722.PubMed
- Dull RO, Tarbell JM, Daves PF: Mechanism of flowmediated signal transduction in endothelial cells: kinetics of ATP surface concentrations. J Vasc Res 1992, 29:410–419.PubMedView Article
- Bergfeld GR, Forrester T: Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnea. Cardiovasc Res 1992, 26:40–47.PubMedView Article
- Strehler BL, McElroy WC: Assay of adenosine triphosphate. In Methods in Enzymology Edited by: Colowick SP, Kaplan NO. 1957, 871–873.View Article
- Kimmich GA, Randles J, Brand JS: Assay of picomole amounts of ATP,ADP, and AMP using the luciferase enzyme system. Anal Biochem 1975,69(1):187–206.PubMedView Article
- Slotte H, Gustafson O, Nylund L, Pousette A: ATP and ADP in human pre-embryos. Hum Reprod 1990, 5:319–322.PubMed
- Miranda KM, Espey MG, Wink DA: A rapid simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric oxide 2001, 5:62–71.PubMedView Article
- Sun J, Zhang X, Broderick , et al.: Measurement of nitric oxide production in biological systems by using Griess reaction assay. Sensors 2003, 3:278–284.View Article
- Moshage H, Kok B, Huizenga JR, Janson LM: Nitrite and nitrate determinations in plasma: a critical evaluation. ClinChem 1995, 41:892–896.
- McAdams A: American Diabetes Association Guideline. 2011. [http://EzineArticles.com/?expert=Angie_McAdams]
- Bogle RG, Coade SB, Moncada S, et al.: Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem Biophys Res Commun 1991, 180:926–932.PubMedView Article
- Ellsworth ML, Forrester T, Ellis CG, et al.: The erythrocyte as a regulator of vascular tone. Am J Physiol 1995, 269:H2155-H2161.PubMed
- Wgner DR, Felber J, Gresser U, et al.: Muscle metabolism and Red cell ATP/ADP concentration during Ergometer in patients with AMPD-Deficiency. Klin Wochenscher 1991, 69:251–255.View Article
- Szabó C, Cuzzocrea S, Zingarelli , et al.: Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 1997, 100:723–735.PubMedView Article
- Srour MA, Bilto YY, Juma M: Susceptibility of erythrocytes from non-insulin-dependent diabetes mellitus and hemodialysis patients, cigarette smokers and normal subjects to in vitro oxidative stress and loss of deformability. Clin Hemorheol Microcirc 2000, 22:173–180.PubMed
- Cignarelli M, Blonda M, Cospite MR, et al.: Alterations of erythrocyte lipid pattern and of some membrane related functions as a consequence of plasma lipid disorder in diabetes mellitus. Diabete Metab FIELD Full Journal Title:Diabete & metabolisme 1983, 9:272–276.
- Spolarics Z, Condon MR, Siddiqi M, et al.: Red blood cell dysfunction in septic glucose-6-phosphate dehydrogenase-deficient mice. Am J Physiol 2004, 286:H2118-H2126.View Article
- Nisoli E, Falcone S, Tonello C, et al.: Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci USA 2004, 101:16507–16512.PubMedView Article
- Wu Z, Puigserver P, Andersson U, et al.: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115–124.PubMedView Article
- Sprague RS, Ellsworth ML, Stephenson AH, et al.: Deformation-induced ATP release from red blood cells requires cystic fibrosis transmembrane conductance regulator activity. Am J Physiol 1998, 275:H1726-H1732.PubMed
- James G, Steven H, Xiangmin Z, et al.: Exercise training enhanced myocardial endothelial nitric oxide synthase (eNOS) function in diabetic Goto-Kakizaki (GK) rats. Cardiovasc Diabetol 2008,7(34):1475–2840.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.